Emerging research suggest Retatrutide , a dual activator targeting both incretin and glucose-dependent insulinotropic polypeptide , could provide a promising advancement for body loss . Preliminary patient trials have demonstrated substantial decreases in body mass , potentially outperforming other obesity medications . However , further assessment